ANZMTG - Australia and New Zealand Melanoma Trials Group Home | Login
ANZMTG - Australia and New Zealand Melanoma Trials Group
 

LOGIN



Please enter your username and password.


Username

Password


  
ANZMTG
 

ANZMTG 03.12 MelMarT Trial - A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma

Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with a primary invasive cutaneous melanomas >=1mm thick to determine differences in the rate of local recurrence and melanoma specific survival. A reduction in margins is expected to improve quality of life in patients.

 
Study status - Current
ANZ Clinical Trials Registry # - ACTRN12614000667617
ClinicalTrials.gov identifier - NCT02385214

Principal Investigator's details:
Prof Michael Henderson
Peter MacCallum Institute
Email: Michael.Henderson@petermac.org

 
ANZMTG coordinator details:
 


Return to Previous Page